Paul Martingell MBA, FCA’s Post

🌟 Since 2019, we have proudly been a B Corp certified company! 🌟 Being a B Corp company is more than just a label—it's a commitment to a new way of doing business. At Chiesi, we believe in generating profit while simultaneously creating shared value for our community and the environment. Our focus is to take meaningful actions on six impact areas (Patient, People, Planet, Governance, Supply Chain and Community). For instance, on planet we have set ambitious targets to achieve zero emissions for our Scope 1 and Scope 2 emissions by 2030, and for Scope 3 emissions by 2035. On patient, we are executing several programs within the framework of health equity to ensure patients get access to the specific individual care they need. For us being a B Corp means a confirmation we are taking the right actions, and it gives direction for the areas we can still improve. March is B Corp month! join us in celebrating this month and our ongoing dedication to sustainability, ethical practices, and positive impact. Together, let's continue to make a difference and be a force for good. #BCorpMonth #BCorpMovement #Sustainability #AtChiesiWeAct  1599/TCP/infolinkedin/BE/03-2024 – MAR 2024

It’s quite nominal to hear the words “culture” “team” “family” “value” etc in any big fortune company set up town halls. What would make a worthwhile difference is to “feel” the same words spelt! stepping to 101 years old, and what a fantastic way to start listening to our leaders who emphasise on ethics, patient centricity, staying curious while being humble! #international #operations #DriveChange #GMA #GBS #bangalore Novo Nordisk

My final QPRs for Argentina with GSK, and I couldn’t be more proud of the progress we’ve made! This past year has been transformative as we worked hard to define and implement a clear way of working, shaping our campaigns with precision and focus. Our efforts have paid off with a CTOR above 7%, which above the benchmark, and we’ve achieved over 24K additional touchpoints compared to Q1. ✨ A key highlight has been the development of digital journeys through the Wizard platform, creating more personalized experiences for HCPs, along with deeply Power BI analysis to ensure we’re making data-driven decisions. Collaboration with the global team has been a crucial part of our success, and I’m incredibly grateful for the teamwork that has brought these results. Together, we’ve set a strong foundation for even greater outcomes! Thank you to everyone who contributed 💡 #Argentina #GSK #DigitalTransformation #PowerBI #CustomerCentric #CampaignSuccess #HealthcareMarketing #ProductManagement #MultichannelStrategy #GrowthMindset #DigitalMarketing #DataAnalysis

”It’s a big drive for me to pass on my experience to new, young talents – and learn from them in return” 🎤 We have met with colleagues from across our global organisation to get their view on ALK as a workplace. Today we bring a perspective from Michael Jentzsch, who joined the company after finishing his studies as a biologist 26 years ago. Today he works in the commercial part of ALK Germany.  Entering ALK as a young scientist, Michael got the opportunity to go to Hørsholm in Denmark to work with the innovative and experienced scientist, Henning Løwenstein, which proved to be important for his decision to stay here for almost three decades: "Henning taught me a lot about allergy research, and working with him truly taught me that ALK is highly scientific and driven by the purpose of helping people with allergy. That really inspired me."  Since his entry to the company, Michael has changed the course of his career many times and has gone from scientist over salesman and to his current position in liaison management. He has always seen 'trust' as a keyword for his development opportunities and for ALK in general:  "There is a general trust here between colleagues across teams and from leaders to employees. We dare to disagree, and we respect one another for having different viewpoints, areas of expertise and development wishes. And that’s what keeps us innovative," Michael says. He underlines how trust is equally essential for ALK externally, and how the internal culture is important for establishing this trust in our company among healthcare professionals and people living with allergy: "The combination of experienced professionals like myself and new, innovative talents in a trustful culture where we all dare to speak up and change the course if necessary is, in my opinion, what keeps ALK innovative and trustworthy and what keeps our working environment inspirational and pleasant," he says. "At the same time, it is a big drive for me personally to be able to pass on the knowledge from my broad, almost three-decades long experience to young, talented forces while also learning a lot from them in return. I cannot think of a better place to work."  If ALK sounds like a workplace for you too, find our current vacant positions at our career site: https://lnkd.in/dUbG_MAr and join us!      #allergy #pharma #innovation #professionaldevelopment #career  

Big Pharma and B Corp are rarely mentioned in the same sentence, which is why Sanofi Consumer Healthcare North America achieving the B Corp certification is worth showcasing. This was a first globally for a large consumer healthcare company, and Sanofi now sits proudly among the 7,000 B Corps globally – of which just 1% are multinationals. “We are honoured to join the B Corp movement alongside other companies aiming to transform business into a force for good,” says Andrew Loucks, Head of North America Consumer Healthcare, Sanofi. So how did the company achieve its B Corp status? And what are its wider sustainability ambitions? #bcorp #healthcare #sustainability #environmentalimpact #socialimpact

At Sanofi, our operations span across 100 countries, and this expansive presence is not just a business strategy, but a beacon of our commitment to embracing diversity. Imagine, if you will, the immense richness of a conversation in a room with one representative from each of these 100 countries. Let's just assume we all understood each other perfectly; can you envision the depth and breadth of insights, the exchange of ideas, and the cultural enlightenment that would transpire? This isn't just a hypothetical scenario at Sanofi; it's a daily reality. The diversity of our team is our strength and our competitive edge. It’s what enables us to serve the health needs of a planet so varied in its people and problems. Each day, we're learning from each other, challenging preconceptions, and contributing to a workplace that is as diverse and vibrant as the world we live in. As I interact with my colleagues from different corners of the globe, like Artem Klochkov (Russian) and Videlis Kamoni (Kenyan), I am reminded of the importance of listening, the value of diverse perspectives, and the impact they have on our innovation and thinking. It's these perspectives that drive us towards more inclusive healthcare solutions that cater to the needs of all, regardless of where they come from. Here's to the richness of our conversations, the depth of our understandings, and the breadth of our perspectives at Sanofi. #SanofiStories #DiversityandInclusion #healthcare

𝗠𝗼𝘀𝘁 𝗰𝗮𝗽𝗶𝘁𝗮𝗹 𝘀𝗽𝗲𝗻𝘁 𝗼𝗻 𝗠&𝗔 𝗼𝗻 𝗖𝗛𝗖 𝗼𝘃𝗲𝗿 𝘁𝗵𝗲 𝗹𝗮𝘀𝘁 𝗱𝗲𝗰𝗮𝗱𝗲 𝗳𝗮𝗶𝗹𝗲𝗱 𝘁𝗼 𝗱𝗲𝗹𝗶𝘃𝗲𝗿 𝗮𝗻𝘆 𝗿𝗲𝘁𝘂𝗿𝗻 Considering the current dynamics at work on CHC with all type of key players, we expect M&A to only accelerate. To address the full potential of M&A on CHC, time for all participants to improve at: i)  Integrating all available M&A learnings in the FMCG/ CHC industry over the last 15 years ii) Finely understanding their strategic framework (ownable strengths to leverage) iii) Determining granular M&A hypotheses (where-to-play/ how-to-win choices) taking into consideration the required success drivers on each segment/ market they have strategic intent on iv) Identifying the right assets & conducting rigorous due diligences v)  Determining optimal value creation cases & corresponding integration models Exciting times for M&A on CHC More on all those points in our latest publication: 𝗙𝗠𝗖𝗚 𝗖𝗘𝗢𝘀: 𝗕𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗧𝗵𝗲 𝗖𝗼𝗱𝗲 𝗢𝗳 𝗢𝘂𝘁𝗽𝗲𝗿𝗳𝗼𝗿𝗺𝗮𝗻𝗰𝗲 𝗢𝗻 𝗖𝗼𝗻𝘀𝘂𝗺𝗲𝗿 𝗛𝗲𝗮𝗹𝘁𝗵 𝗖𝗮𝗿𝗲 (𝗖𝗛𝗖), 𝗞𝗲𝘆 𝗪𝗶𝗻𝗻𝗲𝗿𝘀 & 𝗟𝗼𝘀𝗲𝗿𝘀 𝗔𝗻𝗱 𝗦𝗲𝘃𝗲𝗻 𝗣𝗿𝗲𝗱𝗶𝗰𝘁𝗶𝗼𝗻𝘀 𝗢𝘃𝗲𝗿 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟬 https://lnkd.in/eeCZYWmt To get the corresponding deck, please leave your name in comment & allow us few days 𝗧𝗼 𝗴𝗲𝘁 𝗮𝗹𝗹 𝗼𝘂𝗿 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀, 𝗳𝗼𝗹𝗹𝗼𝘄 𝘂𝘀 & 𝘀𝘂𝗯𝘀𝗰𝗿𝗶𝗯𝗲 𝘁𝗼 𝗼𝘂𝗿 𝗙𝗠𝗖𝗚 𝗖𝗘𝗢 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗻𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿: https://lnkd.in/ea4gy65y #fmcg #cpg #consumerhealth #healthcare Kenvue Sanofi Bayer Bayer | Consumer Health Haleon STADA Group Cooper Consumer Health Karo Healthcare Procter & Gamble Nestlé Nestlé Health Science Unilever Reckitt Church & Dwight Co., Inc. Colgate-Palmolive L'Oréal Pierre Fabre Group Galderma DECIEM | THE ABNORMAL BEAUTY COMPANY The Estée Lauder Companies Inc. Beiersdorf hims & hers Liquid I.V. Nutrafol Perrigo Company plc

𝗠𝗼𝘀𝘁 𝗰𝗮𝗽𝗶𝘁𝗮𝗹 𝘀𝗽𝗲𝗻𝘁 𝗼𝗻 𝗠&𝗔 𝗼𝗻 𝗖𝗛𝗖 𝗼𝘃𝗲𝗿 𝘁𝗵𝗲 𝗹𝗮𝘀𝘁 𝗱𝗲𝗰𝗮𝗱𝗲 𝗳𝗮𝗶𝗹𝗲𝗱 𝘁𝗼 𝗱𝗲𝗹𝗶𝘃𝗲𝗿 𝗮𝗻𝘆 𝗿𝗲𝘁𝘂𝗿𝗻 Considering the current dynamics at work on CHC with all type of key players, we expect M&A to only accelerate. To address the full potential of M&A on CHC, time for all participants to improve at: i) Integrating all available M&A learnings in the FMCG/ CHC industry over the last 15 years ii) Finely understanding their strategic framework (ownable strengths to leverage) iii) Determining granular M&A hypotheses (where-to-play/ how-to-win choices) taking into consideration the required success drivers on each segment/ market they have strategic intent on iv) Identifying the right assets & conducting rigorous due diligences v) Determining optimal value creation cases & corresponding integration models Exciting times for M&A on CHC More on all those points in our latest publication: 𝗙𝗠𝗖𝗚 𝗖𝗘𝗢𝘀: 𝗕𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗧𝗵𝗲 𝗖𝗼𝗱𝗲 𝗢𝗳 𝗢𝘂𝘁𝗽𝗲𝗿𝗳𝗼𝗿𝗺𝗮𝗻𝗰𝗲 𝗢𝗻 𝗖𝗼𝗻𝘀𝘂𝗺𝗲𝗿 𝗛𝗲𝗮𝗹𝘁𝗵 𝗖𝗮𝗿𝗲 (𝗖𝗛𝗖), 𝗞𝗲𝘆 𝗪𝗶𝗻𝗻𝗲𝗿𝘀 & 𝗟𝗼𝘀𝗲𝗿𝘀 𝗔𝗻𝗱 𝗦𝗲𝘃𝗲𝗻 𝗣𝗿𝗲𝗱𝗶𝗰𝘁𝗶𝗼𝗻𝘀 𝗢𝘃𝗲𝗿 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟬 https://lnkd.in/eeCZYWmt To get the corresponding deck, please leave your name in comment & allow us few days 𝗧𝗼 𝗴𝗲𝘁 𝗮𝗹𝗹 𝗼𝘂𝗿 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀, 𝗳𝗼𝗹𝗹𝗼𝘄 𝘂𝘀 & 𝘀𝘂𝗯𝘀𝗰𝗿𝗶𝗯𝗲 𝘁𝗼 𝗼𝘂𝗿 𝗙𝗠𝗖𝗚 𝗖𝗘𝗢 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗻𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿: https://lnkd.in/ea4gy65y #fmcg #cpg #consumerhealth #healthcare Kenvue Sanofi Bayer Bayer | Consumer Health Haleon STADA Group Cooper Consumer Health Karo Healthcare Procter & Gamble Nestlé Nestlé Health Science Unilever Reckitt Church & Dwight Co., Inc. Colgate-Palmolive L'Oréal Pierre Fabre Group Galderma DECIEM | THE ABNORMAL BEAUTY COMPANY The Estée Lauder Companies Inc. Beiersdorf hims & hers Liquid I.V. Nutrafol Perrigo Company plc

𝗠𝗼𝘀𝘁 𝗰𝗮𝗽𝗶𝘁𝗮𝗹 𝘀𝗽𝗲𝗻𝘁 𝗼𝗻 𝗠&𝗔 𝗼𝗻 𝗖𝗛𝗖 𝗼𝘃𝗲𝗿 𝘁𝗵𝗲 𝗹𝗮𝘀𝘁 𝗱𝗲𝗰𝗮𝗱𝗲 𝗳𝗮𝗶𝗹𝗲𝗱 𝘁𝗼 𝗱𝗲𝗹𝗶𝘃𝗲𝗿 𝗮𝗻𝘆 𝗿𝗲𝘁𝘂𝗿𝗻 Considering the current dynamics at work on CHC with all type of key players, we expect M&A to only accelerate. To address the full potential of M&A on CHC, time for all participants to improve at: i) Integrating all available M&A learnings in the FMCG/ CHC industry over the last 15 years ii) Finely understanding their strategic framework (ownable strengths to leverage) iii) Determining granular M&A hypotheses (where-to-play/ how-to-win choices) taking into consideration the required success drivers on each segment/ market they have strategic intent on iv) Identifying the right assets & conducting rigorous due diligences v) Determining optimal value creation cases & corresponding integration models Exciting times for M&A on CHC More on all those points in our latest publication: 𝗙𝗠𝗖𝗚 𝗖𝗘𝗢𝘀: 𝗕𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗧𝗵𝗲 𝗖𝗼𝗱𝗲 𝗢𝗳 𝗢𝘂𝘁𝗽𝗲𝗿𝗳𝗼𝗿𝗺𝗮𝗻𝗰𝗲 𝗢𝗻 𝗖𝗼𝗻𝘀𝘂𝗺𝗲𝗿 𝗛𝗲𝗮𝗹𝘁𝗵 𝗖𝗮𝗿𝗲 (𝗖𝗛𝗖), 𝗞𝗲𝘆 𝗪𝗶𝗻𝗻𝗲𝗿𝘀 & 𝗟𝗼𝘀𝗲𝗿𝘀 𝗔𝗻𝗱 𝗦𝗲𝘃𝗲𝗻 𝗣𝗿𝗲𝗱𝗶𝗰𝘁𝗶𝗼𝗻𝘀 𝗢𝘃𝗲𝗿 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟬 https://lnkd.in/eeCZYWmt To get the corresponding deck, please leave your name in comment & allow us few days 𝗧𝗼 𝗴𝗲𝘁 𝗮𝗹𝗹 𝗼𝘂𝗿 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀, 𝗳𝗼𝗹𝗹𝗼𝘄 𝘂𝘀 & 𝘀𝘂𝗯𝘀𝗰𝗿𝗶𝗯𝗲 𝘁𝗼 𝗼𝘂𝗿 𝗙𝗠𝗖𝗚 𝗖𝗘𝗢 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗻𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿: https://lnkd.in/ea4gy65y #fmcg #cpg #consumerhealth #healthcare Kenvue Sanofi Bayer Bayer | Consumer Health Haleon STADA Group Cooper Consumer Health Karo Healthcare Procter & Gamble Nestlé Nestlé Health Science Unilever Reckitt Church & Dwight Co., Inc. Colgate-Palmolive L'Oréal Pierre Fabre Group Galderma DECIEM | THE ABNORMAL BEAUTY COMPANY The Estée Lauder Companies Inc. Beiersdorf hims & hers Liquid I.V. Nutrafol Perrigo Company plc

As we bring 2023 to a close, I reflect on the progress and momentum the Global Health Unit (GHU) team as achieved over the past twelve months, helping to deliver on Sanofi’s social impact strategy. Over the course of 2023, with our partners, we were able to successfully bring quality, affordable treatments to ~240,000 patients across 31 countries.   Access to sustainable healthcare is increasingly more complex, requiring us to think outside the box by adopting innovative access models and embracing multi sectoral partnerships to have a lasting impact and address disparities in low- to middle-income countries. To create sustainable health care systems, it is imperative we work together. Some of the GHU highlights for 2023 include:   Engaging with local partners, we have supported over 39 training programs across 24 countries in the past year, with many more preparing to launch in 2024. We are delivering on our aim to drive capacity building initiatives that will result in better diagnosis and treatment of patients suffering from non-communicable diseases in the most vulnerable communities. We have helped train over 4200 HCPS and HCWs. We celebrated the first delivery from our Impact brand portfolio to Djibouti in Q4, followed by Tanzania and several other countries by year end. We will continue to bring our dedicated, not-for-profit, Impact brand products to our GHU countries in 2024. I was fortunate to attend and participate in several Global Health panel discussions this year, including events at UNGA, the World Health Summit, and the Impact Europe Impact Week. There were common themes central in many of these discussions including the need for prioritization, collaboration and cooperation to overcome global health challenges. Also, the importance of multi-sectoral engagement, particularly with local agencies and partners who have the greatest understanding of the specific community needs, is critical for sustainable impact. Through our Impact Fund, we are continuing to invest in local entrepreneurs to support the scale and growth of businesses that can help strengthen the communities where they operate. 2023 was an impressive year and we are motivated to keep the momentum going. A BIG THANK YOU to our partners, it would not have been possible without you! https://lnkd.in/eNpFjm4T